Motoaki Imose, Masahito Nagaki, Kiminori Kimura, Shinji Takai, Motohiro Imao, Takafumi Naiki, Yosuke Osawa, Takahiko Asano, Hideki Hayashi, Hisataka Moriwaki – 28 September 2004 – Leflunomide is a novel immunosuppressive and anti‐inflammatory agent for the treatment of autoimmune disease. The aim of this study was to investigate whether leflunomide protects from liver injury induced by concanavalin A (Con A), a T‐cell–dependent model of liver damage. BALB/c mice were injected with 25 mg/kg Con A in the presence or absence of 30 mg/kg leflunomide.

Shoshiro Oe, Eric R. Lemmer, Elizabeth A. Conner, Valentina M. Factor, Per Levéen, Jonas Larsson, Stefan Karlsson, Snorri S. Thorgeirsson – 22 September 2004 – Transforming growth factor β (TGF‐β) is a potent inhibitor of hepatocyte proliferation in vitro and is suggested to be a key negative regulator of liver growth.

Christopher J. Parsons, Blair U. Bradford, Clark Q. Pan, Ellen Cheung, Michael Schauer, Andreas Knorr, Barbara Krebs, Sabine Kraft, Stefan Zahn, Bodo Brocks, Nikki Feirt, Baisong Mei, Myung‐Sam Cho, Roopa Ramamoorthi, Greg Roldan, Paul Ng, Peggy Lum, Claudia Hirth‐Dietrich, Adrian Tomkinson, David A. Brenner – 22 September 2004 – Liver fibrosis is characterized by increased synthesis, and decreased degradation, of extracellular matrix (ECM) within the injured tissue.

Martial Jaume, Sébastien Jacquet, Pierre Cavaillès, Gaëtane Macé, Lionel Stephan, Catherine Blanpied, Cécile Demur, Pierre Brousset, Gilles Dietrich – 22 September 2004 – Fas (CD95)‐induced hepatocyte apoptosis and cytotoxic activity of neutrophils infiltrating the injured liver are two major events leading to hepatitis. Because it has been reported that opioids, via a direct interaction, sensitize splenocytes to Fas‐mediated apoptosis by upregulating Fas messenger RNA (mRNA) and modulated neutrophil activity, we assumed that opioids may participate in the pathophysiology of hepatitis.

Scott T. Magness, Ramón Bataller, Liu Yang, David A. Brenner – 22 September 2004 – Activation of hepatic stellate cells (HSCs) and other resident mesenchymal cells into myofibroblasts expressing alpha smooth muscle actin (αSMA) and collagen I is a key event in liver fibrogenesis. However, the temporal expression profiles of αSMA and collagen I genes in these cells is unknown.

Kim M. Olthoff, Robert S. Brown, Francis L. Delmonico, Richard B. Freeman, Sue V. McDiarmid, Robert M. Merion, J. Michael Millis, John P. Roberts, Abraham Shaked, Russell H. Wiesner, Michael R. Lucey – 21 September 2004 – A national conference was held to review and assess data gathered since implementation of MELD and PELD and determine future directions. The objectives of the conference were to review the current system of liver allocation with a critical analysis of its strengths and weaknesses.

Bruno Roche, Didier Samuel – 21 September 2004 – Key Points 1Long‐term prophylaxis with hepatitis B immune globulin (HBIG) significantly reduces the risk for hepatitis B virus (HBV) recurrence and increases survival. Patients with HBV cirrhosis and / or positive HBV DNA at the time of transplantation have a high risk for recurrence despite HBIG prophylaxis.2Pre–orthotopic liver transplantation (OLT) antiviral treatment using lamivudine (LAM) can suppress HBV replication before transplantation and may induce clinical improvement in a subset of patients.

Richard B. Freeman – 21 September 2004

Richard B. Freeman – 21 September 2004

Margarita Sala, Maria Varela, Jordi Bruix – 21 September 2004 – Key Points 1Liver transplantation is the main option for patients with early HCC who are not optimal candidates for surgical resection.2Shortage of donors is its main limitation, as waiting for a liver allows the tumor to progress and induce exclusion from the waiting list and death.3The absence of randomized controlled trials hinders the establishment of the most effective therapy to prevent tumor progression while waiting.4Live donation may be a cost‐effective approach if optimal results are expected and the mortality risk fo